Paradiem, LLC Alkermes Plc. Transaction History

Paradiem, LLC

$380 Million
Q2 2024

A detailed history of Paradiem, LLC transactions in Alkermes Plc. stock. As of the latest transaction made, Paradiem, LLC holds 10,295 shares of ALKS stock, worth $288,157. This represents 0.07% of its overall portfolio holdings.

Number of Shares

10,295

Previous 19,219 46.43%

Holding current value

$288,157

Previous $520,000 52.31%

% of portfolio

0.07%

Previous 0.13%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 19, 2024	SELL	$23.21 - $27.24 $207,126 - $243,089	-8,924 Reduced 46.43%	10,295 $248,000
Q1 2024 Apr 22, 2024	SELL	$26.4 - $32.56 $30,676 - $37,834	-1,162 Reduced 5.7%	19,219 $520,000
Q4 2023 Feb 05, 2024	SELL	$23.37 - $28.68 $683,502 - $838,803	-29,247 Reduced 58.93%	20,381 $565,000
Q3 2023 Oct 30, 2023	BUY	$27.17 - $31.97 $52,818 - $62,149	1,944 Added 4.08%	49,628 $1.39 Million
Q2 2023 Jul 18, 2023	BUY	$28.34 - $33.63 $21,226 - $25,188	749 Added 1.6%	47,684 $1.49 Million
Q1 2023 Apr 10, 2023	BUY	$25.31 - $29.02 $32,751 - $37,551	1,294 Added 2.84%	46,935 $1.32 Million
Q4 2022 Jan 24, 2023	BUY	$21.94 - $26.24 $101,143 - $120,966	4,610 Added 11.24%	45,641 $0
Q3 2022 Oct 18, 2022	SELL	$22.0 - $31.87 $7,436 - $10,772	-338 Reduced 0.82%	41,031 $916,000
Q2 2022 Jul 11, 2022	BUY	$26.4 - $30.54 $1.09 Million - $1.26 Million	41,369 New	41,369 $1.23 Million
Q1 2022 Apr 15, 2022	SELL	$23.07 - $27.99 $897,492 - $1.09 Million	-38,903 Closed	0 $0
Q4 2021 Feb 03, 2022	BUY	$21.47 - $32.08 $149,388 - $223,212	6,958 Added 21.78%	38,903 $904,000
Q3 2021 Nov 15, 2021	BUY	$23.37 - $32.13 $746,554 - $1.03 Million	31,945 New	31,945 $949,000

Others Institutions Holding ALKS

# of Institutions

346

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.6B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradiem, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Paradiem, LLC with notifications on news.

Account